Change search
ReferencesLink to record
Permanent link

Direct link
Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease
Lund University, Sweden .
Leiden University, Netherlands .
Lund University, Sweden .
University of Lund Hospital, Sweden .
Show others and affiliations
2012 (English)In: Biochimica et Biophysica Acta - General Subjects, ISSN 0304-4165, E-ISSN 1872-8006, Vol. 1820, no 9, 1366-1372 p.Article in journal (Refereed) Published
Abstract [en]

Background: Changes in glycosylation of serum proteins are common, and various glycoforms are being explored as biomarkers in cancer and inflammation. We recently showed that glycoforms detected by endogenous galectins not only provide potential biomarkers, but also have different functions when they encounter galectins in tissue cells. Now we have explored the use of a combination of two galectins with different specificities, to further increase biomarker sensitivity and specificity. less thanbrgreater than less thanbrgreater thanMethods: Sera from 14 women with metastatic breast cancer, 12 healthy controls, 14 patients with IgA-nephritis (IgAN), and 12 patients with other glomerulonephritis were fractionated by affinity chromatography on immobilized human galectin-1 or galectin-8N, and the protein amounts of the bound and unbound fractions for each galectin were determined. less thanbrgreater than less thanbrgreater thanResults: Each galectin bound largely different fractions of the serum glycoproteins, including different glycoforms of haptoglobin. In the cancer sera, the level of galectin-1 bound glycoproteins was higher and galectin-8N bound glycoproteins lower compared to the other patients groups, whereas in IgAN sera the level of galectin-8N bound glycoproteins were higher. less thanbrgreater than less thanbrgreater thanConclusion: The ratio of galectin-1 bound/galectin-8N bound glycoproteins showed high discriminatory power between cancer patients and healthy, with AUC of 0.98 in ROC analysis, and thus provides an interesting novel cancer biomarker candidate. less thanbrgreater than less thanbrgreater thanGeneral significance: The galectin-binding ability of a glycoprotein is not only a promising biomarker candidate but may also have a specific function when the glycoprotein encounters the galectin in tissue cells, and thus be related to the pathophysiological state of the patient. This article is part of a Special Issue entitled Glycoproteomics.

Place, publisher, year, edition, pages
Elsevier , 2012. Vol. 1820, no 9, 1366-1372 p.
Keyword [en]
Galectin-1, Galectin-8, Biomarkers, Cancer, IgA-nephropathy, Serum glycoprotein
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-79630DOI: 10.1016/j.bbagen.2012.01.007ISI: 000306444000008OAI: diva2:543981

Funding Agencies|Swedish Research Council (Vetenskapsradet)||Region Skane||Swedish Cancer Society||Lund University Hospital Foundation||Swedish Research Council|2008-3356|Swedish Foundation for Swedish Research|FFL4|Crafoord Foundation||Swedish Healthcare System||

Available from: 2012-08-13 Created: 2012-08-13 Last updated: 2012-09-07

Open Access in DiVA

fulltext(1041 kB)380 downloads
File information
File name FULLTEXT01.pdfFile size 1041 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Segelmark, Mårten
By organisation
PharmacologyFaculty of Health Sciences
In the same journal
Biochimica et Biophysica Acta - General Subjects
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 380 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 102 hits
ReferencesLink to record
Permanent link

Direct link